Review summarizes therapeutic options for female hypoactive sexual desire disorder, including bremelanotide (PT-141)

The pathophysiology, diagnosis, and treatment of female sexual interest/arousal disorder (FSIAD), also known as hypoactive sexual desire disorder (HSDD), present a complex challenge for both patients and physicians. While Flibanserin was the first FDA-approved pharmacologic treatment for premenopausal women, its utility is constrained by side effects, contraindications, and lack of approval for postmenopausal women. This creates a significant therapeutic gap. Consequently, a range of other potential treatments, including peptide therapies like bremelanotide, hormonal options like testosterone, and various small molecules, are under investigation to provide broader and more effective solutions for women suffering from this distressing condition. The landscape also includes non-pharmacological approaches, highlighting the need for a comprehensive overview of all available and emerging interventions.

This manuscript provides a literature review and clinical data exploration of various therapeutic modalities for female hypoactive sexual desire disorder (HSDD). The authors conducted a survey of existing research to gather information on the efficacy and limitations of pharmacological treatments. The review specifically examined data related to Flibanserin, the first FDA-approved drug for HSDD in premenopausal women. It also assessed evidence for other interventions, including bremelanotide (PT-141), testosterone, buspirone, sildenafil, bupropion, and herbal medications. Furthermore, the review considered non-pharmaceutical interventions such as cognitive behavioral therapy, mindfulness meditation, and pelvic floor therapy. The primary goal was to synthesize current research to better inform providers and stimulate discussion.

The review found that Flibanserin, while being the first FDA-approved treatment for HSDD in premenopausal women, has significant limitations including side effects and contraindications. Several other pharmacological agents have shown some clinical benefit in women with sexual dysfunction. Among these, bremelanotide (PT-141) was identified as a potential therapeutic option. The review also noted that testosterone, buspirone, sildenafil, and bupropion have demonstrated some level of efficacy.

However, the authors caution that the clinical trials for many of these alternative treatments suffer from significant limitations in their design, dosing strategies, or the generalizability of their findings to a broader patient population. Herbal medications such as Herbal vX or Tribulus terrestris were also mentioned as having some evidence of benefit, though subject to similar trial limitations. The paper emphasizes that non-pharmaceutical interventions, including cognitive behavioral therapy and mindfulness meditation, are also viable paths that women may pursue for managing HSDD.

Written by TitrateLab, separately from the study summarized above.